NEW YORK, Sept. 12, 2018 /PRNewswire/ -- Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027SummaryRead the full report: https://www.reportlinker.com/p05537781
Binge Eating Disorder (BED) is associated with a large number of comorbidities including obesity, depression, anxiety, and behavioral disorders such as ADHD and Obsessive Compulsive Disorder (OCD).Key opinion leaders indicated that the selection of pharmacotherapy to treat Binge Eating Disorder (BED) is dependent on each patient's complex combinations of symptoms.The majority of clinical development in Binge Eating Disorder (BED) has focused on drugs that have a primary indication for one of these comorbidities.Binge Eating Disorder (BED) was first noted by Albert Stunkard in 1959, who descriBinge Eating Disorder (BED) the consuming of large quantities of food at irregular intervals and its link to obesity.However, Binge Eating Disorder (BED) was only officially recognized as a distinct eating disorder in 2013, with the publication of the Diagnosis and Statistical Manual, Fifth Edition.Since its recognition as a distinct clinical disorder, awareness of Binge Eating Disorder (BED) has been slowly increasing, but Binge Eating Disorder (BED) is currently only properly diagnosed in a small proportion of cases.The lack of awareness amongst physicians and the public is the major reason that the diagnosis rate of Binge Eating Disorder (BED) is very low, at 3.2%.Binge Eating Disorder (BED) is currently the most common eating disorder in the US.It tends to appear during late adolescence or adulthood, which is later than anorexia nervosa (AN) and bulimia nervosa (BN) typically present.Cognitive behavioural therapy (CBT) is regarded as the first-line treatment for Binge Eating Disorder (BED), but pharmacotherapy is also available as an adjunctive or alternative treatment to CBT.Binge Eating Disorder (BED) is associated with a number of comorbidities, including depression, anxiety, and substance abuse, which must be taken into account when selecting pharmacotherapy.Similarly to other eating disorders, individuals with Binge Eating Disorder (BED) can take decades to recover without treatment, and of those who do receive treatment, some may recover in less than a year, but it more commonly takes 3-7 years.At present only one pharmacotherapy is approved in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)for the treatment of Binge Eating Disorder (BED). However, other therapeutics including antidepressants, anticonvulsants, and obesity drugs, are commonly used as off-label treatments.The Binge Eating Disorder (BED) market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan).The report "Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027", analyzes the current Binge Eating Disorder (BED) pharmacotherapy landscape and provides detailed insights into the market dynamics of this newly recognized disorder.This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for Binge Eating Disorder (BED), and their sales projections within Binge Eating Disorder (BED) over the 2017-2027 forecast period.Scope- Overview of BED, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.- Topline BED market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting BED therapeutics sales in the 7MM.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development and detailed analysis of pipeline products.- Analysis of the current and future market competition in the global BED therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global BED therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BED therapeutics market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.Read the full report: https://www.reportlinker.com/p05537781
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/binge-eating-disorder-bed-opportunity-analysis-and-forecasts-to-2027-300711291.html
SOURCE Reportlinker
